Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity

• US 20080096911A1
• Filed: 12/11/2007
• Published: 04/24/2008
• Est. Priority Date: 11/21/2003
• Status: Active Grant

• Current Assignee: Theravance Biopharma R&D IP, LLC (Theravance Biopharma, Inc.)
• Original Assignee: Mathai Mammen, Sarah Dunham
• Inventors: Mammen, Mathai, Dunham, Sarah
• Granted Patent: US 7,838,535 B2
• Time in Patent Office: Days
• US Class Current: 514/299
• CPC Class Codes: A61K 31/439 the ring forming part of a bridged ring system, e.g. quinuclidine 8-azabicyclo [3.2.1] octanes A61K31/46
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 11/06 Antiasthmatics
• CPC Class Codes: A61P 11/08 Bronchodilators
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 277/68 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
• CPC Class Codes: C07D 417/12 linked by a chain containing hetero atoms as chain links

Abstract

The invention is directed to compounds of formula I:

• • wherein R¹, R², R³, R⁴, R⁵, R⁶, R^7a, R^7b, W, G¹, G², a, b, c, d and m are as defined in the specification, or a pharmaceutically acceptable salt or solvate or stereoisomer thereof. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing such compounds.

Claims

1-30. -30. (canceled)

31. A method for treating a pulmonary disorder, the method comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of formula I:

39. The method of claim 31, wherein the compound is administered by inhalation.

40. The method of claim 31, wherein the compound is administered in multiple doses per day.

41. The method of claim 31, wherein the compound is administered in a single daily dose.

42. The method of claim 31, wherein the compound is administered in a single weekly dose.

43. The method of claim 31, wherein a dose of the compound for treating the pulmonary disorder ranges from about 10 μ

g/day to about 200 μ

g/day.

32. A method of producing bronchodilation in a patient, the method comprising administering to a patient a bronchodilation-producing amount of a compound of formula I:

44. The method of claim 32, wherein a dose of the compound for providing bronchodilation ranges from about 10 μ

g/day to about 200 μ

g/day.

33. A method of treating chronic obstructive pulmonary disease or asthma, the method comprising administering to a patient in need of treatment a therapeutically effective amount of a compound of formula I:

45. The method of claim 33, wherein the compound is administered by inhalation.

46. The method of claim 33, wherein the compound is administered in multiple doses per day.

47. The method of claim 33, wherein the compound is administered in a single daily dose.

48. The method of claim 33, wherein a dose of the compound for treating chronic obstructive pulmonary disease or asthma ranges from about 10 μ

g/day to about 200 μ

g/day.

34-38. -38. (canceled)